The pattern of brain atrophy is closely related to regional NFT accumulation found in AD patients (and quite different to the pattern of amyloid plaques) (Braak and Braak, 1991, McDonald et al., 2009), and thus atrophy remains a valuable biomarker in the evaluation of tau based therapeutics. Here, MAPT is linked to Alzheimer disease.